Skip to Main Content

News & Views

Press Releases

Preclinical Data on Volastra Therapeutics’ Two Novel and Differentiated KIF18A Inhibitors Presented at AACR 2023

NEW YORK, April 16, 2023 – Volastra Therapeutics, a clinical-stage cancer biotechnology company focused on...

Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline

Financing led by founding investors Polaris Partners and ARCH Venture Partners alongside Lilly. Funding will...

Volastra Therapeutics Named One of Fierce Biotech’s “Fierce 15” Companies of 2022

September 12, 2022

NEW YORK, September 12, 2022 – Volastra Therapeutics, an oncology company focused on exploiting chromosomal...

In The News

Lilly-Backed Volastra Enters Clinic with Amgen’s KIF18A Inhibitor

Volastra licenses Amgen molecule for chromosomally unstable cancers

Armed with $60M series A and Lilly’s backing, Volastra enters clinic via Amgen cancer med